サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1427868

過敏性腸症候群（IBS）治療の世界市場レポート 2024年

Irritable Bowel Syndrome (IBS) Treatment Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
過敏性腸症候群（IBS）治療の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

過敏性腸症候群（IBS）治療の市場規模は、今後数年間で急速に成長すると予想されています。 2028年には11.6%の年間複合成長率（CAGR）で42億9,000万米ドルに成長すると予想されます。予測期間で予想される成長は、患者中心の医療モデルの採用、微生物療法の探求、医療におけるブロックチェーンの統合、患者報告アウトカム（PRO）への焦点、医療の導入などの要因に起因すると考えられます。規制の迅速なプログラム、と医療データの相互運用性の進歩。予測期間中に予想される顕著な動向には、デジタルヘルスソリューションの統合、診断技術の進歩、研究開発への投資の増加、医療業界内のコラボレーションとパートナーシップ、と非薬物療法の出現が含まれます。

過敏性腸症候群（IBS）治療市場の予想される成長は、過敏性腸症候群（IBS）の有病率の増加によって推進されています。 IBSは大腸に影響を及ぼす慢性胃腸障害であり、その有病率の上昇は、劣悪なライフスタイル、不健康な食習慣、汚染への曝露、ストレスレベルの上昇に起因すると考えられています。 IBSの治療は、症状を軽減し、重症度と頻度を軽減し、症状を効果的に管理する個人の能力を高めることを目的としています。国際消化器疾患財団（IFFGD）によると、2023年には世界人口の約5～10％が過敏性腸症候群になると予想されており、米国では2,500万～4,500万人が過敏性腸症候群に罹患しているといいます。したがって、IBSの有病率の増加は、過敏性腸症候群（IBS）治療市場の拡大を推進する重要な要因となっています。

過敏性腸症候群（IBS）治療市場の成長は、人口の高齢化によって促進されると予想されます。高齢化人口とは、社会における高齢者の割合の増加を特徴とする人口動態のことを指します。この人口統計グループの人々は、加齢に伴う胃腸症状を管理するために過敏性腸症候群（IBS）治療を利用し、加齢に伴う消化器の健康の変化に対処し、不快感を軽減し全体的な健康状態をサポートすることで生活の質の向上を促進しています。世界保健機関（WHO）が2022年 10月に報告したように、世界の60歳以上の個人人口は急速に増加しており、2050年までに倍増して21億人に達すると予想されています。したがって、人口の高齢化は過敏性腸症候群（IBS）治療市場の成長の重要な推進力です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の過敏性腸症候群（IBS）治療市場の促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の過敏性腸症候群（IBS）治療市場規模実績と成長、2018～2023年
  • 世界の過敏性腸症候群（IBS）治療市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

  • 世界の過敏性腸症候群（IBS）治療市場、薬剤のタイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • ルビプロストン
  • リナクロチド
  • エルクサドリン
  • リファキシミン
  • アロセトロン
  • その他
  • 世界の過敏性腸症候群（IBS）治療市場、適応症別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 便秘を伴うIBS
  • 下痢を伴うIBS
  • 便秘と下痢を繰り返すIBS
  • 世界の過敏性腸症候群（IBS）治療市場、流通チャネル別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 病院薬局
  • オンライン薬局
  • 小売薬局
  • 世界の過敏性腸症候群（IBS）治療市場、エンドユーザー別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 病院
  • クリニック
  • 在宅医療

第7章 地域と国の分析

  • 世界の過敏性腸症候群（IBS）治療市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
  • 世界の過敏性腸症候群（IBS）治療市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 過敏性腸症候群（IBS）治療市場の競合情勢
  • 過敏性腸症候群（IBS）治療市場の企業プロファイル
    • Pfizer Inc.
    • Johnson &Johnson Services Inc.
    • AbbVie Inc.
    • Novartis AG
    • AstraZeneca plc

第31章 その他の大手と革新的な企業

  • Abbott Laboratories
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Biogen Inc.
  • Bausch Health Companies Inc.
  • UCB SA
  • SK Biopharmaceuticals Co. Ltd.
  • Celltrion Healthcare Co. Ltd
  • Ironwood Pharmaceuticals Inc.
  • Sebela Pharmaceuticals Inc.
  • Prometheus Laboratories Inc.
  • RedHill Biopharma Ltd.
  • Ardelyx Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在性分析

第36章 付録

目次
Product Code: r13712

Treatment for irritable bowel syndrome (IBS) involves a range of approaches and interventions directed at addressing disorders in the gastrointestinal tract, common issues that impact the stomach and intestines. The objective of IBS treatment is to alleviate symptoms such as constipation, diarrhea, and abdominal discomfort, reduce the frequency and severity of flare-ups, and enhance overall well-being.

The primary categories of drugs used in irritable bowel syndrome (IBS) treatment include lubiprostone, linaclotide, eluxadoline, rifaximin, alosetron, and others. Lubiprostone, for instance, is a medication employed in treating IBS. It functions as a selective chloride channel activator, facilitating increased fluid secretion in the intestines. The drug is indicated for IBS with constipation, IBS with diarrhea, and IBS with alternating constipation and diarrhea. These medications are distributed through various channels, including hospital pharmacies, online pharmacies, and retail pharmacies, catering to diverse end-users such as hospitals, clinics, and home care settings.

The irritable bowel syndrome (IBS) treatment market research report is one of a series of new reports from The Business Research Company that provides irritable bowel syndrome (IBS) treatment market statistics, including irritable bowel syndrome (IBS) treatment industry global market size, regional shares, competitors with an irritable bowel syndrome (IBS) treatment market share, detailed irritable bowel syndrome (IBS) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the irritable bowel syndrome (IBS) treatment industry. This irritable bowel syndrome (IBS) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The irritable bowel syndrome (ibs) treatment market size has grown rapidly in recent years. It will grow from $2.5 billion in 2023 to $2.77 billion in 2024 at a compound annual growth rate (CAGR) of 10.8%. The growth observed in the historical period can be attributed to several factors, including the increasing prevalence of irritable bowel syndrome (IBS), a rise in patient awareness, the influence of stress and lifestyle factors, the presence of patient advocacy and support groups, and the impact of healthcare reimbursement policies.

The irritable bowel syndrome (ibs) treatment market size is expected to see rapid growth in the next few years. It will grow to $4.29 billion in 2028 at a compound annual growth rate (CAGR) of 11.6%. The anticipated growth in the forecast period can be attributed to factors such as the adoption of patient-centric healthcare models, the exploration of microbial therapies, the integration of blockchain in healthcare, a focus on patient-reported outcomes (PROs), the implementation of regulatory fast-track programs, and advancements in health data interoperability. Prominent trends expected in the forecast period encompass the integration of digital health solutions, advancements in diagnostic technologies, increased investments in research and development, collaborations and partnerships within the healthcare industry, and the emergence of non-pharmacological therapies.

The anticipated growth of the irritable bowel syndrome (IBS) treatment market is driven by the increasing prevalence of irritable bowel syndrome (IBS). IBS is a chronic gastrointestinal disorder affecting the large intestine, and its rising prevalence is attributed to poor lifestyles, unhealthy eating habits, exposure to pollution, and heightened stress levels. Treatment for IBS aims to alleviate symptoms, reduce their severity and frequency, and enhance individuals' ability to manage their conditions effectively. According to the International Foundation for Gastrointestinal Disorders (IFFGD), approximately 5-10% of the global population is expected to have IBS in 2023, with between 25 and 45 million people in the United States affected by the condition. Consequently, the growing prevalence of IBS is a key factor driving the expansion of the IBS treatment market.

The growth of the IBS treatment market is expected to be propelled by the aging population. The aging population refers to a demographic trend characterized by an increasing proportion of elderly individuals within a society. Individuals in this demographic group utilize IBS treatment to manage gastrointestinal symptoms associated with aging, addressing age-related changes in digestive health and promoting a better quality of life by alleviating discomfort and supporting overall well-being. As reported in October 2022 by the World Health Organization (WHO), the global population of individuals aged 60 years and older is rapidly growing and is expected to double by 2050, reaching 2.1 billion. Hence, the aging population is a significant driver for the growth of the IBS treatment market.

A prominent trend in the irritable bowel syndrome (IBS) market is the focus on product innovations by major players. Leading companies in the IBS market are actively engaged in developing new and advanced products to reinforce their market positions. For instance, in April 2022, Ardelyx, a U.S.-based biotechnology company, introduced IBSRELA, a first-in-class treatment for IBS-C in adults. IBSRELA, the first and only NHE3 inhibitor available for treating adult irritable bowel syndrome with constipation (IBS-C), offers a novel mechanism therapy for IBS-C and represents a significant new treatment option for constipation, bloating, and stomach pain associated with this debilitating disorder.

Major companies in the irritable bowel syndrome (IBS) market are adopting a strategic partnership approach to address conditions such as Crohn's disease and ulcerative colitis. Strategic partnerships involve collaboration between companies to leverage each other's strengths and resources for mutual benefits. In October 2023, Sanofi S.A., a France-based pharmaceutical industry company, formed a partnership with Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, aiming to provide treatment for inflammatory bowel disease.

In October 2023, Roche, a Switzerland-based healthcare company, acquired Telavant Holdings for an undisclosed amount. Through this acquisition, Roche gains the rights to develop, manufacture, and market a novel treatment for Irritable Bowel Syndrome (IBS) in the United States and Japan. Telavant Holdings, a U.S.-based biotechnology company, specializes in developing and commercializing innovative therapies for inflammatory and fibrotic diseases.

Major companies operating in the irritable bowel syndrome (ibs) treatment market report are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc. , Astellas Pharma Inc., Biogen Inc., Bausch Health Companies Inc., UCB SA, SK Biopharmaceuticals Co. Ltd., Celltrion Healthcare Co. Ltd., Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Prometheus Laboratories Inc., RedHill Biopharma Ltd., Ardelyx Inc., Protalix Biotherapeutics, Cosmo Technologies Ltd., Renexxion Ireland Ltd., 4D Pharma PLC, Biora Therapeutics Inc.

North America was the largest region in the irritable bowel syndrome (IBS) treatment market in 2023. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the irritable bowel syndrome (ibs) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the irritable bowel syndrome (ibs) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The irritable bowel syndrome (IBS) treatment market includes revenues earned by entities by providing services such as consultation, cognitive-behavioral therapy (CBT), hypnotherapy, psychological therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The irritable bowel syndrome (IBS) market also includes sales of antispasmodics, fiber supplements, laxatives, probiotics, and certain medications targeting gut function. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Irritable Bowel Syndrome (IBS) Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on irritable bowel syndrome (ibs) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for irritable bowel syndrome (ibs) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The irritable bowel syndrome (ibs) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Drug Type: Lubiprostone; Linaclotide; Eluxadoline; Rifaximin; Alosetron; Other Drugs
  • 2) By Indication: IBS With Constipation; IBS With Diarrhea; IBS With Alternating Constipation And Diarrhea
  • 3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
  • 4) By End-Users: Hospitals; Clinics; Homecare Settings
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; AbbVie Inc.; Novartis AG; AstraZeneca plc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Irritable Bowel Syndrome (IBS) Treatment Market Characteristics

3. Irritable Bowel Syndrome (IBS) Treatment Market Trends And Strategies

4. Irritable Bowel Syndrome (IBS) Treatment Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Irritable Bowel Syndrome (IBS) Treatment Market Size and Growth

  • 5.1. Global Irritable Bowel Syndrome (IBS) Treatment Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Irritable Bowel Syndrome (IBS) Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Irritable Bowel Syndrome (IBS) Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Irritable Bowel Syndrome (IBS) Treatment Market Segmentation

  • 6.1. Global Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Lubiprostone
  • Linaclotide
  • Eluxadoline
  • Rifaximin
  • Alosetron
  • Other Drugs
  • 6.2. Global Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • IBS With Constipation
  • IBS With Diarrhea
  • IBS With Alternating Constipation And Diarrhea
  • 6.3. Global Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • 6.4. Global Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Clinics
  • Homecare Settings

7. Irritable Bowel Syndrome (IBS) Treatment Market Regional And Country Analysis

  • 7.1. Global Irritable Bowel Syndrome (IBS) Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Irritable Bowel Syndrome (IBS) Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Irritable Bowel Syndrome (IBS) Treatment Market

  • 8.1. Asia-Pacific Irritable Bowel Syndrome (IBS) Treatment Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Irritable Bowel Syndrome (IBS) Treatment Market

  • 9.1. China Irritable Bowel Syndrome (IBS) Treatment Market Overview
  • 9.2. China Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Irritable Bowel Syndrome (IBS) Treatment Market

  • 10.1. India Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Irritable Bowel Syndrome (IBS) Treatment Market

  • 11.1. Japan Irritable Bowel Syndrome (IBS) Treatment Market Overview
  • 11.2. Japan Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Irritable Bowel Syndrome (IBS) Treatment Market

  • 12.1. Australia Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Irritable Bowel Syndrome (IBS) Treatment Market

  • 13.1. Indonesia Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Irritable Bowel Syndrome (IBS) Treatment Market

  • 14.1. South Korea Irritable Bowel Syndrome (IBS) Treatment Market Overview
  • 14.2. South Korea Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Irritable Bowel Syndrome (IBS) Treatment Market

  • 15.1. Western Europe Irritable Bowel Syndrome (IBS) Treatment Market Overview
  • 15.2. Western Europe Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Irritable Bowel Syndrome (IBS) Treatment Market

  • 16.1. UK Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Irritable Bowel Syndrome (IBS) Treatment Market

  • 17.1. Germany Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Irritable Bowel Syndrome (IBS) Treatment Market

  • 18.1. France Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Irritable Bowel Syndrome (IBS) Treatment Market

  • 19.1. Italy Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Irritable Bowel Syndrome (IBS) Treatment Market

  • 20.1. Spain Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Irritable Bowel Syndrome (IBS) Treatment Market

  • 21.1. Eastern Europe Irritable Bowel Syndrome (IBS) Treatment Market Overview
  • 21.2. Eastern Europe Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Irritable Bowel Syndrome (IBS) Treatment Market

  • 22.1. Russia Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Irritable Bowel Syndrome (IBS) Treatment Market

  • 23.1. North America Irritable Bowel Syndrome (IBS) Treatment Market Overview
  • 23.2. North America Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Irritable Bowel Syndrome (IBS) Treatment Market

  • 24.1. USA Irritable Bowel Syndrome (IBS) Treatment Market Overview
  • 24.2. USA Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Irritable Bowel Syndrome (IBS) Treatment Market

  • 25.1. Canada Irritable Bowel Syndrome (IBS) Treatment Market Overview
  • 25.2. Canada Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Irritable Bowel Syndrome (IBS) Treatment Market

  • 26.1. South America Irritable Bowel Syndrome (IBS) Treatment Market Overview
  • 26.2. South America Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Irritable Bowel Syndrome (IBS) Treatment Market

  • 27.1. Brazil Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Irritable Bowel Syndrome (IBS) Treatment Market

  • 28.1. Middle East Irritable Bowel Syndrome (IBS) Treatment Market Overview
  • 28.2. Middle East Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Irritable Bowel Syndrome (IBS) Treatment Market

  • 29.1. Africa Irritable Bowel Syndrome (IBS) Treatment Market Overview
  • 29.2. Africa Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Irritable Bowel Syndrome (IBS) Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Irritable Bowel Syndrome (IBS) Treatment Market Competitive Landscape
  • 30.2. Irritable Bowel Syndrome (IBS) Treatment Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson & Johnson Services Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. AbbVie Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Novartis AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. AstraZeneca plc
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Irritable Bowel Syndrome (IBS) Treatment Market Other Major And Innovative Companies

  • 31.1. Abbott Laboratories
  • 31.2. Takeda Pharmaceutical Company Limited
  • 31.3. Eli Lilly and Company
  • 31.4. Amgen Inc.
  • 31.5. Astellas Pharma Inc.
  • 31.6. Biogen Inc.
  • 31.7. Bausch Health Companies Inc.
  • 31.8. UCB SA
  • 31.9. SK Biopharmaceuticals Co. Ltd.
  • 31.10. Celltrion Healthcare Co. Ltd
  • 31.11. Ironwood Pharmaceuticals Inc.
  • 31.12. Sebela Pharmaceuticals Inc.
  • 31.13. Prometheus Laboratories Inc.
  • 31.14. RedHill Biopharma Ltd.
  • 31.15. Ardelyx Inc.

32. Global Irritable Bowel Syndrome (IBS) Treatment Market Competitive Benchmarking

33. Global Irritable Bowel Syndrome (IBS) Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Irritable Bowel Syndrome (IBS) Treatment Market

35. Irritable Bowel Syndrome (IBS) Treatment Market Future Outlook and Potential Analysis

  • 35.1 Irritable Bowel Syndrome (IBS) Treatment Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Irritable Bowel Syndrome (IBS) Treatment Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Irritable Bowel Syndrome (IBS) Treatment Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer